ThuyTranMDPhD

Oncology • West Haven, CT

Medical Oncology Yale New Haven Hospital

Join to view full profile

Dr. Tran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tran's full profile

Already have an account?

Office
950 Campbell Ave
West Haven, CT 06516
Phone+1 203-937-3421

Fax+1 203-937-3803

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2019
Yale-New Haven Medical CenterResidency, Internal Medicine, 2013 - 2015
Vanderbilt University School of MedicineClass of 2013

Certifications & Licensure

CT State Medical License 2015 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Biotech Accelerator Award The Blavatnik Fund for Innovation at Yale, 2023
Stephen A. Sherwin ’70 MD Translational Research Fellowship Award 2023

Clinical Trials

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Recruiting
Phase 2
XTX202 in Patients With Advanced Solid Tumors Start of enrollment: 2022 Jan 18
Active, not recruiting
Phase 1, Phase 2
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) Start of enrollment: 2023 Jul 19
Recruiting
Phase 3
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma Start of enrollment: 2022 Dec 12
Suspended
Phase 2
Join now to see all

Publications & Presentations

PubMed

309 citations
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Sarah B. Goldberg, Kurt A. Schalper, Scott N. Gettinger, Amit Mahajan, Roy S. Herbst
The Lancet. Oncology. 2020-05-01
10 citations
[11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis.
Thuy Tran, Jean-Dominique Gallezot, Lucia B. Jilaveanu, Christopher R. Zito, Gabriela Turcu
Molecular Imaging. 2020-01-01
185 citations
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
Harriet M. Kluger, Veronica Chiang, Amit Mahajan, Christopher R. Zito, Mario Sznol
Journal of Clinical Oncology. 2019-01-01

Press Mentions

Yale Study Highlights Unmet Needs for Patients with Melanoma Who Progress or Relapse After Immunotherapy TreatmentAugust 30th, 2024